Take a look at the new report which was commissioned by the Wellcome Trust and conducted by Globe Life Sciences, and presented at the Third Cardiovascular Combination Pharmacotherapy Global Summit, convened by the World Heart Federation on the 8th June 2016, Mexico City, Mexico.
The report assesses the current landscape for the polypill in the primary and secondary prevention of cardiovascular diseases (CVD), with the key aim of providing an update on the accumulated evidence in this field.
